Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has ...

Chinese RNA-based medicine developer Suzhou Ribo Life Science has filed a Hong Kong IPO, aiming to raise new funds for its lead RBD4059 drug candidate for thrombotic diseases. The small-interfering ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

American Soluna Holdings, Inc. has received a scalable loan product worth up to $100 million from sustainable infrastructure investor Generate Capital, PBC. This is stated in the company's message.

Basil writes stories across the U.S. finance file including banks, asset managers, payment firms, insurers, and exchange operators. He also covers initial public offerings on U.S. exchanges and ...